Zhao Jingjie, Guo Xu, Du Yi, Han Yu, Wang Yongzhi, Li Li, Qian Jialin, Li Mingzhen, Wu Huijuan, Golden Teresa, Wu Ning
J Basic Clin Physiol Pharmacol. 2016 Nov 1;27(6):563-567. doi: 10.1515/jbcpp-2015-0148.
Major depressive disorder (MDD) frequently co-occurs with other psychiatric problems. Our previous study showed that ATP1A1 gene expression level was significantly decreased in MDD patients. This research explores the potential correlations between the ATP1A1 expression level reduction and MDD patients' clinical manifestation.
All participant patients were diagnosed by Diagnostic and Statistical Manual of Mental Disorders - 4th edition (DSM-IV). Hamilton rating scale for depression (HAM-D) and anxiety (HAM-A) were applied to group patients into different categories. ATP1A1 expression level was measured by reverse transcript real-time polymerase chain reaction.
ATP1A1 expression levels of all MDD subgroups showed significant reduction compared to the control group (p<0.01). Further, the trend of ATP1A1 expression level reduction is significantly related to MDD patients' HAM-A scores (p<0.01). However, there was no significance between ATP1A1 level and HAM-D scores (p>0.05).
ATP1A1 expression level reduction is related to MDD anxiety score, which may be an explanation for the clinical manifestations and the underlining physiological mechanisms.
重度抑郁症（MDD）常与其他精神问题并发。我们之前的研究表明，MDD患者的ATP1A1基因表达水平显著降低。本研究探讨ATP1A1表达水平降低与MDD患者临床表现之间的潜在相关性。
所有参与研究的患者均根据《精神疾病诊断与统计手册》第四版（DSM-IV）进行诊断。采用汉密尔顿抑郁量表（HAM-D）和汉密尔顿焦虑量表（HAM-A）对患者进行分组。通过逆转录实时聚合酶链反应测量ATP1A1表达水平。
与对照组相比，所有MDD亚组的ATP1A1表达水平均显著降低（p<0.01）。此外，ATP1A1表达水平降低的趋势与MDD患者的HAM-A评分显著相关（p<0.01）。然而，ATP1A1水平与HAM-D评分之间无显著差异（p>0.05）。
ATP1A1表达水平降低与MDD焦虑评分相关，这可能是对临床表现及潜在生理机制的一种解释。
